Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Glucose monohydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Glucose 10% Infusion is a solution of sugar (glucose) in water. Glucose is one of the body's sources of energy. This solution for infusion provides 400 kilocalories per litre. Glucose 10% Infusion is used to:
If another medicine is added to your solution for infusion, always read the Package Leaflet of that medicine. This way you can check to see if that medicine is safe for you to take.
1a
SA-30-02-570
Warnings and precautions
Your doctor will adjust how much solution for infusion you are given according to the results of these tests. These tests will also tell the doctor if you need extra potassium, a chemical in the blood. If required, this can be given into a vein.
Glucose 10% Infusion is a hypertonic (concentrated) solution. Your doctor will take this into account when calculating how much solution to give you. Please tell your doctor if you have or have had any of the following medical conditions.
As Glucose 10% Infusion contains sugar (glucose), it can cause a high level of sugar in the blood (hyperglycaemia). If this occurs, your doctor may:
This may increase the risk of low level of sodium in your blood and can lead to headache, nausea, seizures, lethargy, coma, swelling of the brain and death. Brain swelling increases the risk of death and brain damage. People who are at higher risk of brain swelling are.
When this infusion is given to children the child's doctor will take blood and urine samples to monitor the amount of electrolytes such as potassium in the blood (plasma electrolytes). Newborns, especially those born premature and with low birth weight, are at increased risk of developing a too low or too high level of sugar in the blood (hypo- or hyperglycaemia) and, therefore, need close monitoring during treatment with intravenous glucose solutions, to ensure adequate control of the sugar levels in order to avoid potential long term adverse effects. Low sugar levels in newborns can cause prolonged seizures, coma and brain damage. High sugar levels have been associated with bleeding into the brain, bacterial and
When you are given this infusion, your doctor will monitor:
SA-30-02-570
Pregnancy
fungal infection, damage to the eye (retinopathy of prematurity), infections in the intestinal track (necrotizing enterocolitis), lung problems (bronchopulmonary dysplasia), prolonged length of hospital stay and death.
Glucose solution can be used during pregnancy. However, caution should be taken when glucose solution is used during child birth.
When administered to a newborn baby, the solution bag could be connected to an infusion pump device, which allows exact delivery of the required quantity of solution across the defined time interval. Your doctor or nurse will be monitoring the device to ensure safe administration.
Fertility There are no adequate data of the effect of Glucose on fertility. However, no effect on fertility is expected.
Lactation
Children (including neonates and older children) who are given Glucose 10% Infusion are at higher risk of developing a low sodium level in the blood (hypoosmotic hyponatraemia) and a disorder affecting the brain due to low plasma levels of sodium (hyponatraemic encephalopathy).
There are no adequate data of using Glucose solution during breast-feeding. However, no effect on breastfeeding is expected. Glucose solution can be used during breast-feeding. If another medicine is to be added to your solution for infusion during pregnancy or breast-feeding you should:
Other medicines and Glucose 10% Infusion Tell your doctor or nurse if you are using, have recently used or might use any other medicines.
Driving and using machines
Glucose 10% Infusion and other medicines taken at the same time can affect each other.
Ask your doctor or nurse for advice before driving or using machines.
Do not take Glucose 10% Infusion with certain hormones (catecholamines) including adrenaline or steroids as they can increase the level of sugar in your blood.
Glucose 10% Infusion 3. How you will be given Glucose 10% Infusion 4. Possible side effects 5. How to store Glucose 10% Infusion 6. Contents of the pack and other information
Glucose 10% Infusion
Some medicines act on the hormone vasopressin. These may include:
Glucose 10% Infusion will be given to you by a doctor or nurse. Your doctor will decide on how much you need and when it is to be given. This will depend on your age, weight, clinical condition and the reason for treatment. The amount you are given may also be affected by other treatments you are receiving. You should NOT be given Glucose 10% Infusion if there are particles floating in the solution or if the pack is damaged in any way. Glucose 10% Infusion will usually be given to you through a plastic tube attached to a needle in a vein. Usually a vein in your arm is used to give you the infusion. However, your doctor may use another method to give you the medicine.
Pregnancy, breast-feeding and fertility
Before and during the infusion, your doctor will monitor:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before taking this medicine.
Any unused solution should be thrown away. You should NOT be given an infusion of Glucose 10% Infusion from a bag that has been partly used. SA-30-02-570
Glucose 10% Infusion with food and drink You should ask your doctor about what you can eat or drink.
3a
If you receive more Glucose 10% Infusion than you should
If you are given too much Glucose 10% Infusion (overinfusion) or it is given too fast, or too often, this may lead to the following symptoms:
Stop receiving your Glucose 10% Infusion Your doctor will decide when to stop giving you this infusion. If you have any further questions on the use of this product, ask your doctor or nurse.
4. Possible side effects
If a medicine has been added to the solution for infusion, the added medicine may also cause side effects. These
will depend on the medicine that has been added. You should read the Package Leaflet of the added medicine for a list of possible symptoms.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects can include:
If any side effects occur, the infusion must be stopped.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed below. By reporting side effects you can help provide more information on the safety of this medicine. United Kingdom: Via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard 4a
SA-30-02-570
Ireland: HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: [email protected].
The bag sizes are:
Malta: ADR Reporting Website: www.medicinesauthority.gov.mt/adrportal
Not all pack sizes may be marketed.
Glucose 10% Infusion
Marketing Authorisation Holder and Manufacturer
Keep this medicine out of the sight and reach of children.
Marketing Authorisation Holder:
This medicinal product does not have any special storage conditions.
United Kingdom Baxter Healthcare Ltd Caxton Way, Thetford, Norfolk, IP24 3SE United Kingdom
Glucose 10% Infusion should NOT be given to you after the expiry date which is stated on the bag and the carton after EXP. The expiry date refers to the last day of that month.
Ireland and Malta Baxter Holding B.V. Kobaltweg 49, 3542CE Utrecht, Netherlands
You should not be given Glucose 10% Infusion if there are particles floating in the solution or if the unit is damaged in any way.
Manufacturer: Bieffe Medital S.A. Ctra de Biescas, Senegüé 22666 Sabiñanigo (Huesca) Spain
What Glucose 10% Infusion contains The active substance is glucose (as monohydrate): 100 g per litre.
This leaflet was last revised in August 2020
The only other ingredient is water for injections.
For information about Glucose 10% Infusion or to request this leaflet in formats such as audio or large print please contact the Marketing Authorisation Holder: Tel: +44 (0)1635 206345.
Formula per 250 ml Glucose (as monohydrate): 25 g Formula per 500 ml Glucose (as monohydrate): 50 g Formula per 1000 ml Glucose (as monohydrate): 100 g
What Glucose 10% Infusion looks like and contents of the pack Glucose 10% Infusion is a clear solution, free from visible particles. It is supplied in polyolefin/polyamide plastic bags (Viaflo). Each bag is wrapped in a sealed, protective, outer plastic overpouch.
5a
SA-30-02-570
Glucose 10% w/v Solution for Infusion The following information is intended for healthcare professionals only:
When using an infusion pump all clamps on the intravenous administration set must be closed before removing the administration set from the pump, or switching the pump off. This is required regardless of whether the administration set has an anti free flow device.
Handling and Preparation The solution for infusion should be visually inspected before use.
The intravenous infusion device and administration equipment must be frequently monitored.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use only if the solution is clear, without visible particles and if the container is undamaged. Administer immediately following the insertion of infusion set.
Discard after single use. Discard any unused portion. Do not reconnect partially used bags. Do not store solutions containing additives.
Do not remove unit from overwrap until ready for use.
When introducing additives to Glucose solution aseptic technique must be used.
The inner bag maintains the sterility of the product.
Mix the solution thoroughly when additives have been introduced.
Do not use plastic containers connected in series. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed.
1. Opening a.
Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.
b.
c.
Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
2. Preparation for administration Use sterile material for preparation and administration. a. Suspend container from eyelet support. b. Remove plastic protector from outlet port at bottom of container:
The solution should be administered with sterile equipment using an aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system. Electrolyte supplementation may be indicated according to the clinical needs of the patient. Additives may be introduced before infusion or during infusion through the re-sealable medication port. When an additive is used, verify final osmolariy prior to parenteral administration. Thorough and careful aseptic mixing of any additive is mandatory. Solutions containing additives should be used immediately and not stored. In order to avoid potentially fatal over infusion of intravenous fluids to the neonate, special attention needs to be paid to the method of administration. When using a syringe pump to administer intravenous fluids or medicines to neonates, a bag of fluid should not be left connected to the syringe.
Remove the Viaflo container from the overpouch just before use. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution, as sterility may be compromised. Check the solution for limpidity and absence of foreign matter. If solution is not clear or contains foreign matter, discard the solution
1b
SA-30-02-570
3. Techniques for injection of additive medications
Before adding a drug, verify if it is soluble and stable in water at the pH range of the Glucose 10% Infusion (pH 3.5 to 6.5).
Warning: Additives may be incompatible.
When a compatible medication is added to the Glucose 10% Infusion, the solution must be administered immediately.
To add medication before administration a. Disinfect medication port. b. Using syringe with 19 (1.10 mm) to 22 (0.70 mm) gauge needle, puncture resealable medication port and inject. c. Mix solution and medication thoroughly. For high-density medication such as potassium chloride, tap the ports gently while ports are upright and mix. d. Caution: Do not store bags containing added medications.
Those additives known to be incompatible should not be used.
To add medication during administration a. Close clamp on the set. b. Disinfect medication port. c. Using syringe with 19 (1.10 mm) to 22 (0.70 mm) gauge needle, puncture re-sealable medication port and inject. d. Remove container from IV pole and/or turn to an upright position. e. Evacuate both ports by tapping gently while the container is in an upright position. f. Mix solution and medication thoroughly. g. Return container to in use position, re-open the clamp and continue administration.
4. In use shelf life: Additives The chemical and physical stability of any additive at the pH of Glucose 10% Infusion in the Viaflo container should be established prior to use. From a microbiological point of view, the diluted product must be used immediately unless dilution has taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions are the responsibility of the user.
5. Incompatibilities of additive medications Glucose solution should not be administered simultaneously with, before or after an administration of blood through the same infusion equipment, because haemolysis and clumping can occur. Incompatibility of the medicinal product to be added with the solution in Viaflo container must be assessed before its addition. Baxter and Viaflo are trademarks of Baxter International lnc.
In the absence of incompatibility studies, this solution medicinal product must not be mixed with other medicinal products. The instructions for use of the medicinal product to be added must be consulted. 2b
SA-30-02-570
Glucose 10% w/v Solution for Infusion comes as infusion. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Glucose 10% w/v Solution for Infusion is glucose monohydrate.
Medicines with the same active substance, strength and form include: 5% GLUCOSE INTRAVENOUS INFUSION SOLUTION, Potassium Chloride 0.15 % w/v and Glucose 10 % w/v Solution for Infusion BP, Potassium Chloride 0.15 % w/v and Glucose 5% w/v Solution for Infusion -BP. In total there are 26 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Glucose 10% w/v Solution for Infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Glucose 10% w/v Solution for Infusion is indicated for:
Supply of carbohydrate alone or, as required, during parenteral nutrition.
Prevention and treatment of hypoglycaemia.
Rehydration in case of water loss and dehydration states in patients with high carbohydrate need.
Dilution of compatible medicinal products.
Posology
The dosage and rate of administration of Glucose 10% w/v Solution for Infusion are determined by several factors including the indication for use and the patient's age, weight and clinical condition.
Fluid balance, serum glucose, serum sodium and other electrolytes should be monitored before and during administration, especially in patients with increased non-osmotic vasopressin release (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients co-medicated with vasopressin agonist drugs due to the risk of hyponatraemia. Monitoring of serum sodium is particularly important for physiologically hypotonic fluids. Glucose 10% w/v Solution for Infusion may become extremely hypotonic after administration due to glucose metabolisation in the body (see sections 4.4, 4.5 and 4.8).
Adults and elderly:
The recommended doses in Table 1 serve as a guideline for an average adult with a body weight of approximately 70 kg.
Table 1. Guidance on the Dose for Administration to an Adult (70kg)(*)
Indication
Initial daily dose
Rate of administration
Recommended duration of treatment
Supply of Carbohydrate alone or, as required, during parenteral nutrition
From 500 ml to 3000 ml/day
(from 7 to 40 ml/kg/day)
The recommended maximum administration rate should not exceed the patient's glucose oxidation, as this may cause hyperglycaemia: 5 mg/kg/min (3 ml/kg/h)
No limit on duration - dependent on the clinical condition of the patient
Prevention and treatment of hypoglycaemia
Rehydration in case of water loss and dehydration states in patients with high carbohydrate need
Dilution of compatible medicinal products
From 50 to 250 ml per dose
Dependent on the nature of the additive
Dependent on the nature of the additive
*The largest volumes within recommended dose should be administered in 24 hours to avoid haemodilution.
Paediatric population:
The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by a physician experienced in paediatric intravenous fluid therapy.
The recommended doses in Table 2 serve as a guideline for the paediatric population, as a function of body weight and age.
Table 2. Guidance on the Dose for Administration to Paediatric Population
* The infusion rate, volume and duration of therapy depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by a physician experienced in paediatric intravenous fluid therapy.
Indication
Initial daily dose
Initial Rate of Administration*
Preterm and term newborn infants
Infants and toddlers (1-23 months)
Children (2-11 years)
Adolescents (12 to 16-18 years)
Supply of carbohydrate alone, or, as required, during parenteral nutrition
• 0-10 kg body weight (BW)
100 ml/kg/day
• 10-20 kg body weight (BW)
1000 ml + add 50 ml for each kg BW >10 kg/day
• > 20 kg body weight (BW)
1500 ml + add 20 ml for each kg BW >20 kg/day
6-11 ml/kg/h
(10-18 mg/kg/min)
5-11 ml/kg/h
(9-18 mg/kg/min)
4-8 ml/kg/h
(7-14 mg/kg/min)
4 ml/kg/h
(7-8.5 mg/kg/min)
Prevention and treatment of hypoglycaemia
Rehydration in case of water loss and dehydration states in patients with high carbohydrate need
Dilution of compatible medicinal products
Initial Dose: 50 to 100ml per dose. Not age dependent.
Rate of Administration: Dependant on the nature of the additive. Not age dependent.
NOTE: The largest volumes within recommended dose should be administered in 24 hours to avoid haemodilution.
The maximum rate of administration should not exceed the patient's rate of glucose oxidation, as this may cause hyperglycaemia.
Depending on the patient's clinical condition, a lower flow rate than recommended can be used in order to decrease the risk of undesirable osmotic diuresis.
When the solution is used for dilution or delivery of compatible therapeutic additives for administration intravenously, the directions for use of the additive therapeutic substances will dictate the appropriate volumes for each therapy.
Method of administration:
Administration is usually via a peripheral or central vein.
Glucose 10% w/v Solution for Infusion is a hypertonic solution.
The osmolarity of a final admixed infusion solution must be taken into account when peripheral administration is considered. Please see section 3 for the information about the osmolarity of the solution.
A gradual increase of flow rate should be considered when starting administration of glucose-containing products.
Precautions to be taken before handling or administering the medicinal product
The solution for infusion should be visually inspected before use.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use only if the solution is clear, without visible particles and if the container is undamaged. Administer immediately following the insertion of infusion set.
The solution should be administered with sterile equipment using an aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system.
Electrolyte supplementation may be indicated according to the clinical needs of the patient.
Additives may be introduced before infusion or during infusion through the appropriate port. When making additions, the final osmolarity of the mixture must be measured before administration. Administration of hyperosmolar solutions may cause venous irritation and phlebitis. Thorough and careful aseptic mixing of any additive is mandatory. Solutions containing additives should be used immediately and not stored.
The mixture obtained must be administered through a central or peripheral venous line depending on its final osmolarity.
For information on incompatibilities and preparation of the product and additives, please see sections 6.2 and 6.6.
Please see section 4.4 for the risk of air embolism.
The solution is contra-indicated in patients presenting with:
• Uncompensated diabetes and diabetes insipidus,
• Hyperosmolar coma,
• Haemodilution and extracellular hyperhydration or hypervolaemia,
• Hyperglycaemia and hyperlactataemia,
• Severe renal insufficiency (with oliguria / anuria),
• Uncompensated cardiac failure,
• General oedema (including pulmonary and brain oedema) and ascitic cirrhosis,
• Other known glucose intolerances (such as metabolic stress situations).
• Hypersensitivity to the active substance. See sections 4.4 and 4.8 for corn allergies.
The contra-indications related to any medicinal product that is added to the glucose solution should be considered.
Glucose intravenous infusions are usually isotonic solutions. In the body, however, glucose containing fluids can become extremely physiologically hypotonic due to rapid glucose metabolization (see section 4.2).
Dilution and other effects on serum electrolytes
Depending on the tonicity of the solution, the volume and rate of infusion and depending on a patient's underlying clinical condition and capability to metabolize glucose, intravenous administration of glucose can cause:
• Hyperosmolality, osmotic diuresis and dehydration
• Hypoosmolality
• Electrolyte disturbances such as
- hypo- or hyperosmotic hyponatraemia (see below),
- hypokalaemia,
- hypophosphatemia,
- hypomagnesaemia,
- overhydration/hypervolemia and, for example, congested states, including pulmonary congestion and oedema.
The above effects do not only result from the administration of electrolyte-free fluid but also from glucose administration.
Hyponatraemia:
Patients with non-osmotic vasopressin release (e.g. in acute illness, pain, post-operative stress, infections, burns, and CNS diseases), patients with heart-, liver- and kidney diseases and patients exposed to vasopressin agonists (see section 4.5) are at particular risk of acute hyponatraemia upon infusion of hypotonic fluids.
Acute hyponatraemia can lead to acute hyponatraemic encephalopathy (brain oedema) characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain oedema are at particular risk of severe, irreversible and life-threatening brain injury.
Children, women in the fertile age and patients with reduced cerebral compliance (e.g. meningitis, intracranial bleeding, and cerebral contusion) are at particular risk of the severe and life-threatening brain swelling caused by acute hyponatraemia.
Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.
Particular caution is advised in patients at increased risk of water and electrolyte disturbances that could be aggravated by increased free water load, hyperglycaemia or possibly required insulin administration (see below).
In case of prolonged administration or high glucose dose, care should be taken to avoid hypokalaemia by monitoring plasma potassium levels and administering a potassium supplement as appropriate.
Special clinical monitoring is required at the beginning of any intravenous infusion.
Hyperglycaemia
• Rapid administration of glucose solutions may produce substantial hyperglycaemia and a hyperosmolar syndrome.
• To reduce the risk of hyperglycaemia-associated complications, the infusion rate must be adjusted and/or insulin administered
• Intravenous glucose should be administered with caution in patients with, for example:
˗ impaired glucose tolerance (such as in patients with renal failure or diabetes mellitus or in the presence of sepsis, trauma, or shock)
˗ severe malnutrition (risk of precipitating a refeeding syndrome),
˗ thiamine deficiency, e.g., in patients with chronic alcoholism (risk of severe lactic acidosis due to impaired oxidative metabolization of pyruvate),
- patients with ischemic stroke or severe traumatic brain injury
Avoid infusion within the first 24 hours following head trauma. Monitor blood glucose closely as early hyperglycaemia has been associated with poor outcomes in patients with severe traumatic brain injury.
- newborns
Effects on Insulin Secretion
Prolonged intravenous administration of glucose and associated hyperglycaemia may result in decreased rates of glucose-stimulated insulin secretion.
Hypersensitivity Reactions
• Hypersensitivity/infusion reactions, including anaphylactic/anaphylactoid reactions, have been reported with Glucose solution (see section 4.8). Solutions containing glucose should therefore be used with caution, if at all, in patients with known allergy to corn or corn products (see section 4.3).
• The infusion must be stopped immediately if any signs or symptoms of a suspected hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.
Refeeding syndrome
• Refeeding severely undernourished patients may result in the refeeding syndrome that is characterized by the shift of potassium, phosphorus, and magnesium intracellularly as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. Careful monitoring and slowly increasing nutrient intakes while avoiding overfeeding can prevent these complications.
Paediatric population:
The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy, and should be determined by a consulting physician experienced in paediatric intravenous fluid therapy.
In order to avoid potentially fatal over infusion of intravenous fluids to the neonate, special attention needs to be paid to the method of administration. When using a syringe pump to administer intravenous fluids or medicines to neonates, a bag of fluid should not be left connected to the syringe.
When using an infusion pump all clamps on the intravenous administration set must be closed before removing the administration set from the pump, or switching the pump off. This is required regardless of whether the administration set has an anti free flow device.
The intravenous infusion device and administration equipment must be frequently monitored.
Paediatric glycaemia related issues
Newborns – especially those born premature and with low birth weight - are at increased risk of developing hypo- or hyperglycaemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycaemic control in order to avoid potential long term adverse effects. Hypoglycaemia in the newborn can cause prolonged seizures, coma and cerebral injury. Hyperglycaemia has been associated with intraventricular haemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, prolonged length of hospital stay, and death.
Paediatric hyponatraemia-related issues
• Children (including neonates and older children) are at increased risk of developing hypoosmotic hyponatraemia as well as for developing hyponatraemic encephalopathy.
• Plasma electrolyte concentrations should be closely monitored in the paediatric population.
• Rapid correction of hypoosmotic hyponatraemia is potentially dangerous (risk of serious neurologic complications). Dosage, rate, and duration of administration should be determined by a physician experienced in paediatric intravenous fluid therapy.
Geriatric Use
• When selecting the type of infusion solution and the volume/rate of infusion for a geriatric patient, consider that geriatric patients are generally more likely to have cardiac, renal, hepatic, and other diseases or concomitant drug therapy.
Blood
• Glucose solution (an aqueous, i.e., electrolyte-free glucose solution) should not be administered through the same equipment as whole blood, as haemolysis and pseudoagglutination can occur.
Risk of Air Embolism
• Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.
• Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.
• Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
For method of administration and precautions to be taken before handling or administering the medicinal product, please see also section 4.2.
Both the glycaemic effects of Glucose solution and its effects on water and electrolyte balance should be taken into account when using Glucose solution in patients treated with other substances that affect glycaemic control, or fluid and/or electrolyte balance.
Concomitant administration of catecholamines and steroids decreases the glucose up-take.
Drugs leading to an increased vasopressin effect
The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and increase the risk of hospital acquired hyponatraemia following inappropriately balanced treatment with i.v. fluids (see sections 4.2, 4.4 and 4.8).
• Drugs stimulating vasopressin release, e.g.: Chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors, 3.4-methylenedioxy-N-methamphetamine, ifosfamide, antipsychotics, narcotics
• Drugs potentiating vasopressin action, e.g.: Chlorpropamide, NSAIDs, cyclophosphamide
• Vasopressin analogues, e.g.: Desmopressin, oxytocin, terlipressin
Other medicinal products increasing the risk of hyponatraemia also include diuretics in general and antiepileptics such as oxcarbazepine.
No interaction studies have been performed.
When a medicinal product is added, the nature of the drug and its use during pregnancy and lactation have to be considered separately.
Intrapartum maternal intravenous glucose infusion may result in foetal insulin production, with an associated risk of foetal hyperglycaemia and metabolic acidosis as well as rebound hypoglycaemia in the neonate.
Pregnancy
Glucose solution can be used during pregnancy. However, caution should be exercised when glucose solution is used intrapartum.
Glucose solution should be administrated with special caution for pregnant women during labour particularly if administered in combination with oxytocin due to the risk of hyponatraemia (see section 4.4, 4.5 and 4.8).
Fertility
There are no adequate data of the effect of Glucose on fertility. However, no effect on fertility is expected.
Lactation
There are no adequate data of using Glucose solution during lactation. However, no effect on lactation is expected. Glucose solution can be used during lactation.
None known.
The administration of Glucose 10% w/v Solution for Infusion can lead to the development of:
• Hyperglycaemia,
• Fluid-balance disturbances (hypervolaemia),
• Electrolyte disturbances (hypokalaemia, hypomagnesaemia, and hypophosphataemia).
The following Post-marketing adverse reactions have been reported in the post-marketing experience, listed by MedDRA System Organ Class (SOC), then, where feasible, by Preferred Term in order of severity.
Table 3. Tabulated list of adverse reactions
System Organ Class
Adverse reaction (MedDRA term)
Frequency
Immune system disorders
Anaphylactic reaction**
Hypersensitivity **
Not known (*)
Metabolism and nutrition disorders
Electrolyte disturbances Hyperglycaemia
Hemodilution
Hypervolaemia
Hospital Acquired Hyponatraemia***
Skin and subcutaneous tissue disorders
Sweating
Rash
Nervous system disorders
Hyponatraemic encephalopathy***
General disorders and administration site conditions
Chills, Shivering
Pyrexia, Febrile reaction, Fever
Infection at site of injection
Thrombophlebitis
Infusion site reactions including,
• Infusion site phlebitis
• Infusion site erythema
Investigations
Glycosuria
(*) cannot be estimated from the available data
**Potential manifestation in patients with allergy to corn, see section 4.4 .
*** Hospital acquired hyponatraemia may cause irreversible brain injury and death due to development of acute hyponatraemic encephalopathy (see sections 4.2 and 4.4).
Other adverse reactions reported with glucose injection/infusions include:
• Adverse reactions reported when glucose is used with parenteral nutrition:
- Hepatic failure, Hepatic cirrhosis, Hepatic fibrosis, Cholestasis, Hepatic steatosis, Blood bilirubin increased, Hepatic enzyme increased, Cholecystitis, Cholelithiasis
- Pulmonary vascular precipitates
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard
Prolonged administration or rapid infusion of large volumes of Glucose 10% w/v Solution for Infusion may cause hyperosmolarity and hyponatraemia, dehydration, hyperglycaemia, hyperglycosuria, osmotic diuresis (due to hyperglycaemia) and water intoxication and edema. Severe hyperglycaemia and hyponatraemia may be fatal (see sections 4.4 and 4.8).
In case of suspected overdose, treatment with Glucose 10% must be stopped immediately. Management of overdose is symptomatic and supportive, with appropriate monitoring.
Ask anything about Glucose 10% w/v Solution for Infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.